Skip to main content
. Author manuscript; available in PMC: 2024 Apr 10.
Published in final edited form as: Clin Cancer Res. 2021 Jan 20;27(10):2792–2797. doi: 10.1158/1078-0432.CCR-20-3761

Figure 1.

Figure 1.

Waterfall plot showing patient and tumor molecular characteristics, treatment and percent change in tumor size. (New metastases were graphed as 21% progression. Treatment line refers to therapies in the metastatic setting.

Patients ID 4,5 and 8 also received bevacizumab. ID 6 also received lapatinib and trastuzumab.